The Systemic Pruritus Paradox: Unraveling the Mysteries of Dry Skin in Systemic Disease

Abstract

Introduction: Dry skin (xerosis) and pruritus are among the most common dermatological complaints, yet their significance often extends beyond primary skin disorders. Both symptoms are frequently associated with systemic diseases such as chronic kidney disease (CKD), liver dysfunction, diabetes mellitus, and thyroid disorders. Despite their prevalence and impact on quality of life, no comprehensive synthesis has evaluated xerosis and pruritus as cross-cutting manifestations of systemic disease.

Method: A systematic review was conducted following PRISMA guidelines. Major databases were searched for studies published in the last 10 years that reported xerosis or pruritus in patients with systemic diseases. Eligible studies included observational cohorts, cross-sectional analyses, and clinical trials. Data were extracted on prevalence, pathophysiological mechanisms, and quality-of-life outcomes.

Results and Discussion: Fourteen studies met inclusion criteria, encompassing over 40,000 patients across hepatobiliary, renal, endocrine, and metabolic disorders. Xerosis prevalence ranged from 41% in CKD to over 80% in diabetes mellitus, while pruritus prevalence varied from 28.9% in chronic liver disease to 61.7% in cholestatic cohorts. Mechanistic studies highlighted roles for immune dysregulation (IL-6, IL-31), altered lipid composition, impaired sweat/sebaceous gland activity, and neurocutaneous sensitization. Across conditions, xerosis and pruritus were consistently associated with sleep disturbance, anxiety, depression, and reduced quality of life. Several studies also linked moderate-to-severe pruritus with higher hospitalization and mortality risk in CKD.

Conclusion: Xerosis and pruritus are highly prevalent, clinically significant manifestations of systemic disease. Their recognition as more than secondary complaints underscores their potential as low-cost diagnostic markers and targets for multidisciplinary management. Standardized assessment tools and interventional trials are urgently needed to determine whether effective treatment of these symptoms can improve both dermatological and systemic outcomes.